Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase 1/2 4Phase 3 2Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Uveal Melanoma 1

Interventions

Nivolumab 10pembrolizumab 6Ipilimumab 6Niacinamide 3Magnetic Resonance Spectroscopy 3Itraconazole 3Cyclophosphamide 3Biopsy 3resiquimod 2encorafenib 2durvalumab 2calcipotriene 2binimetinib 2aldesleukin 2Radiotherapy 2Oncolytic Virotherapy 2Niacin 2MART-1 Antigen 2Interleukin-2 2Imiquimod 2HhAntag691 2Fluorouracil 2Ascorbic Acid 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Vorinostat × Dermatologic × Clear all
NCT03022565 2020-02-06

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

University of Miami

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡